drugset / Trial / NCT04915586

Short Duration High Intensity Intrapleural Alteplase With Pulmozyme in Pleural Infection Management

NCT04915586

Completed 30 enrolled National University of Malaysia
NaSingle-groupOpen-labelTreatment

Summary

The aim of this study was to assess the efficacy of the modified regimen short duration intrapleural 16mg alteplase (Actilyse, Boehringer Ingelheim) with 5mg DNase (Pulmozyme Hoffmann-La Roche Ltd) in patients with pleural infection.

Timeline

Start
2019-12-30
Primary completion
2020-12-31
Completion
2020-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Alteplase Protein / enzyme biologic 16 mg
Subject dornase alfa Protein / enzyme biologic 5 mg

Indications